ARQT Earnings Date: Nov 4, 2026 (Estimated) — Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ARQT's next earnings date?
Arcutis Biotherapeutics, Inc. (ARQT) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.18 on revenue of $142.6M.
How did ARQT do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Arcutis Biotherapeutics, Inc. posted EPS of $0.11 versus the $0.06 estimate, a beat of 120.0%. Revenue was $129.9M against a $118.9M estimate. The stock's 1-day post-earnings move was -2.5%.
How much does ARQT stock move after earnings?
ARQT beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.6% (up or down) in the day after earnings.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.06 | 0.11 | +120.00% | $129.9M | ✅ Beat | -2.47% | -3.03% | -12.69% |
| 2026-05-06 | Q1 2026 | -0.05 | -0.09 | -80.00% | $105.4M | ❌ Miss | -14.52% | -10.26% | -12.16% |
| 2026-02-25 | Q4 2025 | 0.07 | 0.13 | +85.71% | $129.5M | ✅ Beat | +5.78% | -10.70% | -17.14% |
| 2025-10-28 | Q3 2025 | -0.10 | 0.06 | +160.00% | $99.2M | ✅ Beat | +27.04% | +26.07% | +56.47% |
| 2025-08-06 | Q2 2025 | -0.16 | -0.13 | +18.75% | $81.5M | ✅ Beat | -8.07% | +1.76% | +11.88% |
| 2025-02-25 | Q4 2024 | -0.27 | -0.09 | +66.67% | $71.4M | ✅ Beat | +8.36% | +9.84% | +35.00% |
| 2024-11-06 | Q3 2024 | -0.42 | -0.33 | +21.43% | $44.8M | ✅ Beat | +7.66% | +8.39% | +28.36% |
| 2024-08-14 | Q2 2024 | -0.57 | -0.42 | +26.32% | $30.9M | ✅ Beat | -11.27% | -12.94% | +11.27% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY23 · $21.5M total
| Segment | Share | Revenue | YoY | Q4 FY22 | Q3 FY23 | Q4 FY23 |
|---|---|---|---|---|---|---|
| Product | 98.0% | $21.1M | +611.8% | $3.0M | $8.1M | $21.1M |
| Other Revenue | 2.0% | $420K | — | — | $30.0M | $420K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.